Fate Therapeutics (FATE) Enterprise Value (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Enterprise Value came in at -$174.8 million in Q1 2026, up 27.29% YoY from -$137.3 million in Q1 2025, and up 14.16% on a QoQ basis from -$203.7 million in Q4 2025.
Fate Therapeutics (FATE) Enterprise Value (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Enterprise Value data on file, last reported at -$174.8 million in Q1 2026.
- Quarterly Enterprise Value rose 27.29% year-over-year to -$174.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$174.8 million (up 27.29% YoY) and the FY2025 annual result came in at -$203.7 million, up 27.02% from the prior year.
- Enterprise Value advanced to -$174.8 million in Q1 2026, from -$203.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$174.8 million in Q1 2026 to a low of -$573.8 million in Q1 2022.
- A 5-year average of -$344.5 million and a median of -$315.2 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value gained 6.2% — and 2025, when it surged 37.31%.
- Tracing FATE's Enterprise Value over 5 years: stood at -$436.2 million in 2022, then increased by 27.75% to -$315.2 million in 2023, then rose by 11.46% to -$279.1 million in 2024, then increased by 27.02% to -$203.7 million in 2025, then climbed by 14.16% to -$174.8 million in 2026.
- The last three Enterprise Value figures came in at -$174.8 million (Q1 2026), -$203.7 million (Q4 2025), and -$215.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -174.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -174.82 Mn |
| Dec 31, 2025 | -203.66 Mn |
| Sep 30, 2025 | -215.42 Mn |
| Jun 30, 2025 | -222.83 Mn |
| Mar 31, 2025 | -240.43 Mn |
| Dec 31, 2024 | -279.07 Mn |
| Sep 30, 2024 | -296.92 Mn |
| Jun 30, 2024 | -304.88 Mn |
| Mar 31, 2024 | -383.54 Mn |
| Dec 31, 2023 | -315.18 Mn |
| Sep 30, 2023 | -349.73 Mn |
| Jun 30, 2023 | -377.94 Mn |
| Mar 31, 2023 | -408.90 Mn |
| Dec 31, 2022 | -436.23 Mn |
| Sep 30, 2022 | -505.14 Mn |
| Jun 30, 2022 | -568.85 Mn |
| Mar 31, 2022 | -573.77 Mn |
| Dec 31, 2021 | -615.91 Mn |
| Sep 30, 2021 | -678.70 Mn |
| Jun 30, 2021 | -695.60 Mn |